Award Number: DAMD17-02-1-0014

TITLE: Trace Elements and the Development of Prostate Cancer

PRINCIPAL INVESTIGATOR: Arthur J. Sytkowski, M.D.

CONTRACTING ORGANIZATION: Beth Israel Deaconess Medical Center
Boston, Massachusetts 02215

REPORT DATE: January 2005

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
**Trace Elements and the Development of Prostate Cancer**

**Title and Subtitle:**

Selenium is an essential nutrient that may have an important preventive action in prostate cancer. We have identified a human gene in prostate cells, designated hSP56, the mouse homologue of which may mediate selenium's growth inhibitory effect in vitro and anti-cancer effect in vivo. hSP56 is expressed by LNCaP but not by PC-3 and is reversibly downregulated by androgen. We hypothesize that hSP56 protein may play a role in the anti-cancer effects of selenium in the prostate gland. To test this hypothesis we will 1) study the molecular properties of hSP56 protein, including its binding of selenium, 2) study the role of hSP56 in the prostate cancer phenotype in vitro using gain-of-function and loss-of-function approaches, 3) investigate the effect of overexpression or downregulation of hSP56 on in vivo tumor growth in SCID mice, and 4) determine the distribution of hSP56 expression in primary human tumors and in adjacent normal prostate cells. This work will lead to a new understanding of prostate cancer regulation and the role of selenium in normal and malignant prostate growth and spread.
Table of Contents

Cover ................................................................. 1
SF 298 .............................................................. 2
Introduction ...................................................... 4
Body ................................................................. 4
Key Research Accomplishments ......................... 11
Reportable Outcomes ........................................... 11
Conclusions ...................................................... 12
References ....................................................... 12
Appendices ....................................................... 13
INTRODUCTION

The essential trace element selenium was first associated with cancer risk more than two decades ago. Whereas a deficiency in dietary selenium is associated with an increased incidence of several cancers, including prostate, dietary selenium supplementation has been shown to reduce the incidence of prostate and other cancers. We recently discovered that a human selenium binding protein, hSP56, is expressed by the slowly growing androgen sensitive LNCaP cell line but not by the more rapidly growing, highly metastatic androgen insensitive PC-3 cell line. Treatment of LNCaP cells with androgen results in downregulation of hSP56 expression and a concomitant increase in cell growth, suggesting that hSP56 may mediate the anti-cancer effect of selenium in humans. We hypothesize that hSP56 is a growth regulating protein that modulates the phenotype of human prostate cancer and may mediate the anti-cancer effect of dietary selenium. The study will demonstrate the location of selenium binding on the hSP56 molecule. It will also demonstrate that changes in hSP56 expression and selenium alter the in vitro and in vivo phenotype of human prostate cancer cells. LNCaP, cells that express endogenous hSP56 constitutively, will be transfected with an inducible antisense construct, thereby allowing hSP56 to be downregulated. These cells will be used in loss-of-function experiments, that is, examining the in vitro and in vivo phenotype of cells in which hSP56 has been downregulated. PC-3 cells, which do not express hSP56, will be transfected with an inducible hSP56 sense construct, thereby allowing gain-of-function experiments, that is, studying the effect of increased hSP56 expression on the PC-3 phenotype. Lastly, using in situ hybridization and immunohistochemistry, the pattern of hSP56 expression in primary tumors and bone marrow metastases will be elucidated.

BODY

Experimental Procedures- New Techniques Developed

Construction of bacterial expression plasmids-- A cDNA clone that contains the largest hSP56 cDNA of 1721 bp was isolated. It contains a complete open reading frame of hSP56 with more sequence in both 5' and 3' untranslated regions than our original clone (NCBI accession number BC009084). The original hSP56 cDNA cloned by Chang et al. [1](NCBI accession number U29091) is 1429 bp in length with minimal 5' and 3' untranslated sequences. The bacterial expression vectors used were pTrcHisA and pTrcHisB for producing recombinant hSP56 without or with N-terminal (His)₆ fusion (Invitrogen). The complete coding cDNA of hSP56 protein was cloned into the Neo I and Eco RI sites of pTrcHisA for non-fusion expression and into BamH I and Eco RI sites of pTrcHisB fused in-frame with the N-terminal (His)₆ sequence for producing (His)₆-fusion protein in E. coli. For N-terminal (His)₆-fusion protein expression, the translational initiation codon was removed. The DNA fragments for both (His)₆ fusion and non-fusion expression were generated by high fidelity PCR reaction using the cDNA clone of hSP56-BC009084 as template. Restriction fragments containing hSP56 coding sequences were obtained by digestion with respective enzymes and gel purified before the ligation reaction. The PCR primer pairs were SEBP1 (5'-CCGGGATCCGGCTACGAAATGTGGGAATTG-3') and SEBP2 (5'-CCGGAAATTCATACATCCAGGTAGGTGGCAG-3') for (His)₆ fusion construct (pTrcHisB-hSP56nHis) and SEBP3 (5'-CATGCCATGGCTACGAAATGTGGGAG-3') and SEBPC4 (5'-CCGGAAATTCACAGGAACATGGTGGTCAG-3') for non-fusion expression (pTrcHisA-hSP56). These
bacterial expression constructs are all verified by DNA sequencing to ensure the fidelity of the subcloning. The resulting expression constructs pTrcHisA-hSP56 and pTrcHisB-hSP56nHis were transformed into E. coli TOP10F' by electroporation. Host cells harboring the expression plasmids were grown in LB broth with 100 μg/ml ampicillin. To express the recombinant N-terminal (His)_6 fusion human selenium-binding protein (rhSP56nHis) of 503 amino acid residues or the recombinant human selenium-binding protein (rhSP56) of 472 residues, 1 mM of IPTG was added to the culture medium to induce expression.

Construction of mammalian cell expression plasmids-- The mammalian expression vector was pcDNA4/TO/mycHisA (Invitrogen). The hSP56 cDNA was excised out from vector pSPORT6 which contains hSP56-BC009084 cDNA fragment without the putative 3’ SECIS sequence and subsequently was ligated into Hind III/Eco RI sites of pcDNA4/TO/mycHisA in the multiple cloning sequences.

Construction of SECIS functional assay plasmid-- A mammalian expression vector containing human type I deiodinase (107-112-D10) was cleaved with Hind III and Not I to remove the functional SECIS sequence and replaced with a 265 bp DNA fragment from the 3’ UTR of hSP56 (107-112-D10/hSP56UTR). Oligonucleotide primer SECISP1 (5’-CCCAAGCTTTAGACTCCACCCTCATCACCC-3’) and SECISP2 (5’-ATAGTTTAGCCGCAGAAGACAGGTTCCAGGT-3’) corresponding to positions 1467-1484 and 1685-1704 of hSP56 BC009084 were synthesized and used in PCR amplification. The PCR primers were designed to include Hind III and Not I sites at their termini. High fidelity PCR reaction with primers SECISP1 and SECISP2 using hSP56-BC009084 plasmid DNA as template generated DNA fragment of the hSP56UTR, and this DNA was tested for its potential selenocysteine insertion function after cleaved with restriction enzymes inserted into the Hind III and Not I sites of expression construct 107-112-D10.

Transient Expression of hSP56 in prostate cancer cells-- Prostate carcinoma cell lines LNCaP and PC-3 were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum. Twenty-four hours prior to the transfection treatment, the cells were plated in 2 ml of medium in 6-well plates at a density of 2 x 10^5 cells/well. For transient expression of hSP56, 5 μg of expression construct DNA was added to the cells with Lipofectin reagent from LifeTechnologies following the manufacturer’s protocols.

Deiodinase assay (based on [2])-- Transient transfection of SECIS functional assay plasmids was done by the calcium phosphate method. Human embryonic kidney (HEK293) cells were used as host cells. Cells were plated onto 60 mm culture dishes in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum three days before the transfection. Cells were transfected with 10 μg of 107-112-D10/hSP56UTR and 4 μg of pUHD15 plasmid that encodes a protein necessary for transcriptional activation of the 107-112-D10 promoter. An additional 3 μg of an expression vector containing the human growth hormone cDNA under the control of the hamster sarcoma virus thymidine kinase promoter were co-transfected to allow quantification of the transfection efficiency. As a positive control, the expression construct 107-112-D10 containing the functional SECIS of human type I deiodinase was used. Cells were harvested two days after transfection by scraping and were lysed by sonication. Cells were washed and resuspended in 0.1 M potassium phosphate, pH 6.9, containing 1 mM EDTA, 0.25 M sucrose, and 10 mM dithiothreitol. The active deiodinase was assayed by its ability to 5'-deiodinate ^125^l reverse T3. Total protein of 10 μg was added to the reaction containing 1 μM ^125^l reverse T3, 10 mM dithiothreitol in a volume of 300 μl. After incubation at 37 °C for 30 min., ^125^l release was quantified. The detected
deiodinase activity was normalized to the amount of growth hormone secreted into the medium. Each expression construct was tested in duplicate transfection, and each sample was assayed twice.

Progress Made On Each Task

TASK 1: Study the cellular and molecular properties of hSP56 protein

The first cDNA sequence of hSP56 identified by Chang et al. and confirmed by us contains only minimum sequences in both 5’ and 3’ untranslated regions. The deposition of DNA sequencing results of the Human Genome Project into the NCBI databases provided hSP56 cDNA clones with better annotation. The addition of more than 250 bp of 3’ untranslated sequence suggested the possibility that hSP56 mRNA contains a potential selenocysteine insertion sequence (SECIS) in its 3’ UTR. In other mammalian selenoproteins, selenium is incorporated into the protein by a specific mechanism. It involves a UGA codon and a 3’ regulatory SECIS sequence in the mRNA, tRNA charged with selenocysteine, and other protein factors. If this were the case with hSP56, that is, if hSP56 were a selenocysteine-containing protein, then much of our proposed research under Task 1 would have to be redesigned. Therefore, we took advantage of the well established SECIS activity assay and prepared a mammalian expression construct plasmid that contains the open reading frame of the human deiodinase sequence and replaced its own functional SECIS sequence with the DNA sequence of hSP56 3’ UTR. This method has been used to evaluate whether potential SECIS sequences function to direct the insertion of a selenocysteine residue, which is required for the enzyme to be active (Figure 1). Importantly, we found no deiodinase activity in cells transfected with our test construct DNA, thus proving that hSP56 is not a selenocysteine-containing protein, but rather a selenium binding protein, validating our Task 1 experiments.

![SECIS activity assay](image)

Figure 1. Deiodinase assay shows that 3’ UTR of hSP56 does not contain an SECIS. 1) Negative control; 2) Positive control; 3) hSP56 3’UTR shows no activity.

We became aware of a study that found carbonic anhydrase and SP56 to be the most abundant non-heme proteins in the erythrocytes of the subterranean mole rat (Spalax ehrenbergi) [3]). We prepared lysates of normal human erythrocytes and leukocytes and subjected them to SDS-PAGE and western blotting with anti-hSP56 antibodies. We detected large amounts of hSP56 in the erythrocyte lysates but not in the leukocyte lysates. Except for the small population of reticulocytes, there is no active protein synthesis in erythrocytes. Therefore, hSP56 must a very stable, long lived protein. Furthermore, its presence in large amounts in human erythrocytes may suggest that it plays a transport role for selenium in the circulation.
Lastly, we found that purified, recombinant hSP56 can bind selenium stably in vitro. We incubated bacterially expressed hSP56 with increasing concentrations of $^{75}$Se (supplied as selenite in nitric acid) followed by SDS-PAGE under non-reducing conditions. The gel was dried and subjected to autoradiography. Each sample showed robust binding of $^{75}$Se as evidence by a band of radioactivity corresponding to the position of hSP56 on the gel.

**TASK 2: Investigate the role of hSP56 and selenium in the prostate cancer phenotype in vitro**

We began gain-of-function studies involving the transient transfection and over-expression of hSP56 in prostate cancer cells. We discovered that expression of hSP56 triggers apoptosis in PC-3 cells. In order to begin to study hSP56 through “gain-of-function” experiments, we transfected PC-3 cells, in which hSP56 expression is low to absent, and subjected them to biochemical selection. However, the cells stably transfected with hSP56 failed to proliferate, unlike that vector-transfected controls, suggesting a growth inhibiting action of hSP56 protein on PC-3 carcinoma. Transient transfection of PC-3 with hSP56 revealed that expression of hSP56 protein resulted in the induction of apoptosis (Figure 2). Cells were grown to 65% confluence and then treated with paclitaxel (to induce apoptosis-positive control) or transfected with the expression vector pcDNA4-hSP56 or control vector. After 48 hr, cells were lysed and poly(ADP-ribose) polymerase (PARP) protein was detected by SDS-PAGE and western blot. The 116 kDa intact PARP protein is hydrolyzed by caspase-3 to an 85 kDa fragment upon activation of the apoptotic pathway and, therefore, serves as a marker for apoptosis. As seen in Figure 2, lane 1, no apoptosis was detected in control cells (intact 116 kDa PARP protein). However, a prominent 85 kDa band, indicative of apoptosis, was detected in lysates of paclitaxel treated cells as expected (lane 2) and, importantly, in cells transfected with hSP56 (lane 3). Western blot using our anti-hSP56 antibody confirmed expression of the hSP56 protein in the transfected cells (not shown). These results provide strong evidence that induction of apoptosis may be one part of the anti-cancer action of hSP56.
Analysis of hSP56’s amino acid sequence using various algorithms fails to reveal any protein sites or signatures (such as enzymatic active sites, leucine zipper, etc.) that could provide a clue to function. This, coupled with the single report that hSP56 may have some role in intra-Golgi protein transport, leads us to hypothesize that hSP56 operates through interaction with one or more other proteins. Venkateswaran et al. showed that selenomethionine (SeMeth) inhibited the growth of LNCaP but not PC-3 cells in vitro, and they speculated that this difference might be due to the fact that LNCaP cells express hSP56, whereas PC-3 cells do not [4]. Recently, we initiated both “loss-of-function” (LOF) and “gain-of-function” (GOF) studies to test this hypothesis. The results provide convincing evidence that hSP56 plays an important role in mediating the growth-inhibiting action of SeMeth on prostate cancer cells. For LOF studies, we used siRNA nucleotides to down-regulate hSP56 in LNCaP. Using accepted rules, we designed [5] and had synthesized five siRNA hSP56 sequences. Western blots showed that one of the five down-regulated hSP56 mRNA by 70-80%. We then grew LNCaP in the absence or presence of the siRNA and in the absence or presence of specified concentration of SeMeth followed by sequential cell counts. As expected, in the absence of the siRNA, SeMeth inhibited LNCaP growth in a concentration-dependent manner. However, down-regulating hSP56 by addition of siRNA markedly reduced the growth-inhibiting action of SeMeth; the cells grew more rapidly (data not shown). For GOF studies, we stably transfected PC-3 cells with an hSP56 cDNA expression vector and confirmed stable expression of the protein by western blot. Then we carried out growth assays in the absence or presence of SeMeth as above (Figure 3). We found that SeMeth had no significant inhibitory action on the growth of the wild-type PC-3 cells. Importantly, SeMeth inhibited the growth of the hSP56-expressing PC-3 cells markedly, strongly supporting the hypothesis that hSP56 plays a critical role in mediating the growth-inhibiting action of SeMeth on prostate cancer cells.
inhibiting action of SeMeth on prostate cancer cells. Furthermore, we showed that transfection of PC-3 cells with hSP56 markedly inhibited their growth in soft agar (Figure 4). To begin to test the hypothesis that hSP56 operates through protein-protein interaction, we have begun to identify potential interacting proteins using yeast two-hybrid screening of a normal human prostate cDNA library with full-length hSP56 as bait (Table 1).

<table>
<thead>
<tr>
<th>Protein degradation</th>
<th>cDNA identified</th>
<th>No. of (+) clones</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEDD8 conjugating enzyme (Ubc12)</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>pVHL-interacting deubiquitinating enzyme 1 (VDU1)</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>poly-ubiquitin C</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>G protein signaling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rho GDP dissociation inhibitor</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Abi-1/e3B1</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Phosphorylation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARK5</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>PI4 kinase type II-beta</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Metabolism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enoyl-CoA hydratase</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>Aldolase C</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>Others</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Integral membrane protein BRI3</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Similar to oxidation resistance gene OXR1</td>
<td></td>
<td>1</td>
</tr>
</tbody>
</table>

The plasmids from the positive clones were isolated, sequenced by automated DNA sequencing, and BLAST searches were performed for identification. Number of the clones containing regions from the same protein is also indicated. Fifteen more potential interacting proteins of which the DNA sequences are still to be analyzed are not included in this table.
TASK 3: Determine effects of altered hSP56 expression and dietary selenium on tumor growth and spread in vivo.

- We completed training of Dr. Wang and Ms. Wellenstein in animal surgery.

- In December 2003, we began a study in SCID mice of comparing the growth of PC-3 cells with that of PC-3 cells expressing hSP56. The results indicated that PC-3 cells expressing hSP56 grow much slower than the wild type cells. In some animals, they did not grow at all, demonstrating the grow inhibiting action of hSP56 in human prostate cancer cells in vivo.

- We are now developing LNCaP cells with hSP56 stably down-regulated using RNAi technology in order to carry out loss-of-function experiments in vivo.

TASK 4: To carry out a pilot study to determine the distribution of hSP56 in primary tumors, metastatic foci and normal prostate tissue and correlate with Gleason grade.

We determined that our antibodies to hSP56 protein are very useful for immunohistochemical detection of the protein, an important aim of the proposed research. We transplanted LNCaP cells orthotopically into the ventral prostate of SCID mice. After tumors had formed, they were excised, fixed, embedded in paraffin and mounted onto glass slides. After deparaffinization, the slides were incubated with specified dilutions of anti-hSP56 antibody. Then biotinylated anti-rabbit secondary antibody was applied followed by avidin-biotin peroxidase complex. After washing in PBS, the color was developed with diaminobenzidine. Hematoxylin was used as a counterstain. Figure 5 shows intensely staining hSP56 protein in the cytoplasm of the LNCaP cells. The cells differ in the apparent amount of hSP56 protein expressed. The murine tissue compressed by the tumor does not stain for hSP56, illustrating the specificity of the antibody. This specificity is seen especially clearly in Figure 6. In this photomicrograph, hSP56-expressing LNCaP cells, on the left, are seen invading mouse prostate glandular tissue, which is decidedly negative. The ability of this highly specific antibody to differentiate among cells expressing hSP56 at different levels will greatly enhance our immunohistochemistry studies of human tumors and metastatic foci.

![Figure 5. Immunohistochemical detection of hSP56 protein in LNCaP tumor cells.](image)

![Figure 6. hSP56 protein in LNCaP tumor cells (left) invading SCID mouse prostate (right).](image)
• We identified the tumor specimens to be used in the study.
• We have optimized the staining protocol.
• Staining of the tumor specimens was carried out in the Fall of 2004. They are now being reviewed by our collaborating pathologist.

KEY RESEARCH ACCOMPLISHMENTS

• Construction of bacterial expression plasmids
• Construction of mammalian cell expression plasmids
• Construction of SECIS functional assay plasmid
• Transient Expression of hSP56 in prostate cancer cells
• Deiodinase assay
• Discovered more 5' and 5' UTR sequence of hSP56 cDNA
• Proved that hSP56 is not a selenocysteine-containing protein
• Discovered that transient over-expression of hSP56 induces apoptosis in PC-3 cells
• Demonstrated that our antibodies to hSP56 gave excellent results in immunohistochemistry
• Discovery of high levels of hSP56 in human erythrocytes
• Prepared gain-of-function PC-3 cell line expressing hSP56
• Showed that selenomethionine inhibits growth of PC-3/hSP56 cells but not PC-3 cells in vitro
• Showed that PC-3/hSP56 cells grow poorly in soft agar compared to PC-3 cells
• Identified several potential hSP56 interacting proteins by yeast two hybrid assay
• Initiated a growth study of PC-3 and PC-3/hSP56 cells in SCID mice
• Began human tumor immunohistochemistry Task 4.

REPORTABLE OUTCOMES

• Applied for funding from NIH
• Manuscript describing above results completed and submitted
• Second manuscript in preparation
CONCLUSIONS

hSP56 is a selenium binding protein. It is found in human erythrocytes. It appears to mediate the growth inhibiting action of selenomethionine on human prostate cancer cells. It has numerous potential interacting partners. It may function by interacting with one or more of these proteins. hSP56 upregulation by pharmaceuticals or gene therapy may prove to be an effective treatment for prostate cancer.

REFERENCES


APPENDIX: Personnel Receiving Pay From the Research Effort (listed alphabetically)

- Glenn Bubley, MD
- Emma Downs
- Rosemary Panza
- Peter Solar, PhD
- Arthur J. Sytkowski, MD
- Yuxun Wang, PhD
- Jin Ron Zhou, PhD